Literature DB >> 15832017

Accumulation of metals and minerals from phosphate binders.

Donald A Molony1, Bhamidipati Murthy.   

Abstract

Metals and minerals that depend on renal clearance may accumulate to toxic levels in patients with marginal kidney function. Toxicities of aluminum-based phosphate binders became apparent approximately 25 years ago. Nephrologists now recognize cardiovascular calcification may follow use of calcium-based phosphate binders. Five lessons can be learned: (1)safety must not be assumed in absence of data; (2) all evidence for causal linkage of toxicities from therapeutics must be considered, including animal data; (3) clinical trials are unlikely to reveal the spectrum of problems from long-term drug exposure; (4) complications can remain unrecognized until late in post-introduction surveillance; (5) minerals important for normal function can be toxic with excess accumulation. Introduction of new agents necessitates caution - it is difficult to change practice once a therapeutic is commonplace. Lessons learned about hazards of past phosphate binders must be applied judiciously when evaluating long-term risks/safety of novel metal-based binders such as lanthanum carbonate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15832017     DOI: 10.1159/000083712

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  5 in total

1.  Ferric citrate controls phosphorus and delivers iron in patients on dialysis.

Authors:  Julia B Lewis; Mohammed Sika; Mark J Koury; Peale Chuang; Gerald Schulman; Mark T Smith; Frederick C Whittier; Douglas R Linfert; Claude M Galphin; Balaji P Athreya; A Kaldun Kaldun Nossuli; Ingrid J Chang; Samuel S Blumenthal; John Manley; Steven Zeig; Kotagal S Kant; Juan Jose Olivero; Tom Greene; Jamie P Dwyer
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

2.  K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?

Authors:  Mingxin Wei; Hulya Taskapan; Khaled Esbaei; Sarbjit Vanita Jassal; Joanne M Bargman; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2006-12-11       Impact factor: 2.370

Review 3.  Pharmacology, efficacy and safety of oral phosphate binders.

Authors:  Alastair J Hutchison; Craig P Smith; Paul E C Brenchley
Journal:  Nat Rev Nephrol       Date:  2011-09-06       Impact factor: 28.314

Review 4.  Lanthanum carbonate: safety data after 10 years.

Authors:  Alastair J Hutchison; Rosamund J Wilson; Svetlana Garafola; John Brian Copley
Journal:  Nephrology (Carlton)       Date:  2016-12       Impact factor: 2.506

5.  Trace elements in end-stage renal disease--unfamiliar territory to be revealed.

Authors:  Adrian Covic; Paul Gusbeth-Tatomir
Journal:  BMC Nephrol       Date:  2009-06-02       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.